Skip Navigation


European Heart Journal Advance Access originally published online on May 4, 2005
European Heart Journal 2005 26(14):1449-1450; doi:10.1093/eurheartj/ehi320
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/14/1449    most recent
ehi320v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Thimme, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thimme, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Recombinant streptokinase: evidences from clinical use: reply

Michael Thimme

ZLB Behring GmbH
D 35002 Marburg
Germany
Tel: +49 6421 39 4130
Fax: +49 6421 39 4146
E-mail address: michael.thimme@zlbbehring.com

The first 10% of the full text of this article appears below.

In our paper ‘Comparative analysis of the activity and content of different streptokinase preparations’,1 we only mentioned the results of the chromogenic assay for the activity measurement. However, the respective data were also confirmed by a clot-lysis assay as a second assay, which was performed in accordance with the current European Pharmacopoeia. Furthermore, wherever feasible, we also evaluated an additional sample from . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?